Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study.

M, Humbert; C, Taillé; L, Mala; Gros V, Le; J, Just; M, Molimard

doi:10.1183/13993003.02523-2017

Public

Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study.

Shared by NobleBlocks on May 10, 2018 • 12:00 AM UTC

Authors:

Humbert M

Taillé C

Mala L

Abstract

Omalizumab is a monoclonal anti-IgE antibody used to treat severe allergic asthma (SAA). The aim of the STELLAIR study was to determine the importance of pre-treatment blood eosinophil count as a predictive measure for response to omalizumab.This retrospective real-life study was conducted in France...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!